WuXi Biologics (Cayman) (WuXi Biologics (Cayman)) Interest Expense : $-22 Mil (TTM As of Jun. 2023)

View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. WuXi Biologics (Cayman)'s interest expense for the six months ended in Jun. 2023 was $ -11 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2023 was $-22 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. WuXi Biologics (Cayman)'s Operating Income for the six months ended in Jun. 2023 was $ 357 Mil. WuXi Biologics (Cayman)'s Interest Expense for the six months ended in Jun. 2023 was $ -11 Mil. WuXi Biologics (Cayman)'s Interest Coverage for the quarter that ended in Jun. 2023 was 32.45. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

WuXi Biologics (Cayman) Interest Expense Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Interest Expense Chart

WuXi Biologics (Cayman) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-2.80

-6.54

-6.15

-9.24

-22.20

WuXi Biologics (Cayman) Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial													-2.88	-3.39	-5.98	-11.01	-11.16

WuXi Biologics (Cayman) Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-22 Mil.

WuXi Biologics (Cayman) (OTCPK:WXXWY) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

WuXi Biologics (Cayman)'s Interest Expense for the six months ended in Jun. 2023 was $-11 Mil. Its Operating Income for the six months ended in Jun. 2023 was $357 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2023 was $539 Mil.

WuXi Biologics (Cayman)'s Interest Coverage for the quarter that ended in Jun. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Jun. 2023 )	/	Interest Expense (Q: Jun. 2023 )
	=	-1	*	357.093	/	-11.006
	=	32.45

The higher the ratio, the stronger the company's financial strength is.

WuXi Biologics (Cayman) (WuXi Biologics (Cayman)) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (OTCPK:WXXWY) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

WXIBF:USA 2269:Mexico 02269:Hong Kong 1FW1:Germany 1FW2:Germany

Address

No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092

Website

https://www.wuxibiologics.com

WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.